ProQR Therapeutics appointed Chris Hart as chief data and AI officer and Thomas Wolf as a strategic AI advisor to its board, with AX-0811 target engagement data expected in early January 2027. ProQR says the appointments support its plan to scale artificial intelligence across medicine discovery and development.

Key Highlights

  • Chris Hart, PhD, has been appointed ProQR’s chief data and AI officer.
  • Thomas Wolf, PhD, will join ProQR’s Board of Directors as a strategic AI advisor.
  • ProQR expects AX-0811 target engagement data in early January 2027.

ProQR Therapeutics N.V. (NASDAQ: PRQR) is a Pharmaceuticals: Major company. Chris Hart has been appointed chief data and AI officer, while Thomas Wolf is set to join the Board of Directors as a strategic AI advisor.

ProQR Adds Hart and Wolf to AI Leadership

Nvidia (NASDAQ: NVDA) has recently agreed to acquire Hugging Face. The appointments concern both management and board-level strategic advice. ProQR said the pair bring complementary expertise relevant to integrating artificial intelligence into drug discovery and development.

AX-0811 Marks First AI-Enabled Clinical Program

The company described AX-0811 as its first program identified through its AI-enabled discovery engine to reach clinical testing. The stated development plan includes target engagement data for AX-0811 in early January 2027. ProQR also said its expanded AI strategy is directly supporting ongoing development programs.